Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence
ActiveAtlas Opportunity Score 99/100
FL-DOH-FCIF-FY27-2026FloridaFlorida Department of HealthHealth SystemHealthcare ProviderHospitalCancer Research & Clinical TrialsCancer ScreeningClinical Quality Improvement

Florida Cancer Innovation Fund FY 2026-27

Florida has approximately $70 million available through the FY 2026-27 Florida Cancer Innovation Fund for high-impact cancer innovation, clinical and translational work, implementation, technology, screening, nutrition-based prevention and related initiatives. Eligible Florida-based organizations may request up to $2 million; the first rolling application period closes September 25, 2026 at 11:59 PM ET.

FundingApproximately $70 million available statewide; applicants may request up to $2 million.
DeadlinePeriod 1: September 25, 2026 at 11:59 PM ET. Period 2: November 6, 2026 at 11:59 PM ET. The FOA describes Period 3 as November 7-December 18, 2026 but contains an internal submission-deadline inconsistency; applicants should confirm the final Period 3 deadline with Florida DOH.
Last verified2026-08-31
Required next actionReview the controlling FY 2026-27 Funding Opportunity Announcement and confirm the applicant meets Florida-based institutional eligibility; select an eligible high-impact cancer innovation, clinical, translational, implementation, screening, nutrition or technology project; confirm the project can be completed within the required 12-month period; prepare the application in the Florida Cancer Connect Collaborative portal and submit for the September 25 first-period deadline or a later rolling period if appropriate.

Broad Eligibility

Florida-based licensed or certified healthcare providers, facilities and entities meeting at least one qualifying criterion in the FOA, including certain rural or underserved hospitals, rural hospitals, Critical Access Hospitals, pediatric specialty hospitals, oncology clinics or treatment facilities, low- or no-cost cancer screening providers, accredited cancer programs, biomedical research organizations and institutions training cancer-screening, diagnostic or treatment practitioners.

Atlas Analysis

One of Florida's highest-value currently actionable healthcare funding opportunities. The fund strongly favors implementation-ready, high-impact cancer innovation with direct patient or system benefit, including clinical and translational approaches, technology, screening, nutrition-based prevention and generic-drug repurposing. Rural, underserved and nonmetropolitan impact is strategically important. Atlas uses the official FY 2026-27 FOA as the controlling source and flags its internal Period 3 deadline inconsistency rather than guessing.

Current status: Active. Florida Department of Health released the FY 2026-27 Cancer Innovation Fund Funding Opportunity Announcement on August 14, 2026, with approximately $70 million available and awards of up to $2 million for 12-month cancer innovation projects.

Current application window: Period 1 applications are due September 25, 2026 at 11:59 PM ET. Additional review periods close November 6 and December 18, 2026. Questions for the current FOA closed August 28, with agency responses scheduled for September 1.

Source reconciliation: Atlas is using the controlling FY 2026-27 FOA and the live portal dashboard for the current dates. A secondary portal application-process page still displays older August 26 and October 22 period dates and should not be used as the controlling deadline source. The FOA’s key-points section and portal dashboard both identify September 25, November 6, and December 18 as the three FY 2026-27 review cutoffs.

Eligible applicants: Florida-based licensed or certified healthcare providers, facilities, or entities meeting the statutory cancer-program criteria described in the FOA, including qualifying cancer treatment, screening, research, clinical education, rural hospital, and related organizations. Collaborations are encouraged.

Allowable commercial pathway: The FOA permits subcontracted services when justified and pre-approved in the Public Health Research Program Budget Template, and budgets may include personnel, equipment, supplies, and technical support. Equipment above $5,000 requires additional Florida Department of Health review and approval. Vehicles, construction, renovation, and remodeling are not allowable.

N9+ Direct Vendor Fit: 93/100 — HIGH FIT. Dr. Miltie is not established as a direct eligible applicant under the FOA. The strongest defensible pathway is vendor/subcontractor participation through an eligible Florida cancer organization, positioning N9+ as remote clinical examination technology and technical support within an integrated cancer care, decentralized care, underserved-access, rural-access, or implementation project. Florida has previously funded a Cancer CARE Beyond Walls model using digital technology and remote patient monitoring to bring portions of cancer care into patients’ homes, which strengthens the fit for a carefully designed remote-care proposal.

Atlas capture priority: High. The combination of explicit technology/equipment/technical-support allowability, subcontracting, scalable care-model objectives, and prior state investment in remote cancer care supports immediate partner-target identification and a grant-specific N9+ capture strategy. No applicant-facing outreach should occur without organization-specific eligibility verification, a complete package, duplicate-send review, and the required pre-send QA.

Source verificationOfficial government source · cancerinnovation.floridahealth.govAtlas last verified this record 2026-08-31. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗